Sweden-based NorthX Biologics (“NorthX”), which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience (“Abera”) for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12. NorthX has recently established an innovation hub to offer support to partners in achieving their long-term drug development goals. The company’s ability to handle new ways of working and experience with unique development demands was crucial in Abera’s decision-making. Abera Bioscience is a biotechnology company that develops vaccine candidates based on its proprietary vaccine platforms. The company’s main candidate, Ab-01.12, is a universal
The post NorthX Biologics signs GMP manufacturing collaboration agreement with Abera Bioscience appeared first on Pharma Mirror Magazine.
